Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27440271)

  • 1. Preclinical Benefit of Hypoxia-Activated Intra-arterial Therapy with Evofosfamide in Liver Cancer.
    Duran R; Mirpour S; Pekurovsky V; Ganapathy-Kanniappan S; Brayton CF; Cornish TC; Gorodetski B; Reyes J; Chapiro J; Schernthaner RE; Frangakis C; Lin M; Sun JD; Hart CP; Geschwind JF
    Clin Cancer Res; 2017 Jan; 23(2):536-548. PubMed ID: 27440271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of Hypoxia-Activated Prodrug Evofosfamide after Conventional Adjuvant Therapy Enhances Therapeutic Outcome and Targets Cancer-Initiating Cells in Preclinical Models of Colorectal Cancer.
    Haynes J; McKee TD; Haller A; Wang Y; Leung C; Gendoo DMA; Lima-Fernandes E; Kreso A; Wolman R; Szentgyorgyi E; Vines DC; Haibe-Kains B; Wouters BG; Metser U; Jaffray DA; Smith M; O'Brien CA
    Clin Cancer Res; 2018 May; 24(9):2116-2127. PubMed ID: 29476017
    [No Abstract]   [Full Text] [Related]  

  • 3. Combined Antitumor Therapy with Metronomic Topotecan and Hypoxia-Activated Prodrug, Evofosfamide, in Neuroblastoma and Rhabdomyosarcoma Preclinical Models.
    Zhang L; Marrano P; Wu B; Kumar S; Thorner P; Baruchel S
    Clin Cancer Res; 2016 Jun; 22(11):2697-708. PubMed ID: 26719428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Theranostic application of lipiodol for transarterial chemoembolization in a VX2 rabbit liver tumor model.
    van Breugel JMM; Geschwind JF; Mirpour S; Savic LJ; Zhang X; Duran R; Lin M; Miszczuk M; Liapi E; Chapiro J
    Theranostics; 2019; 9(13):3674-3686. PubMed ID: 31281506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in osteolytic breast cancer murine models.
    Liapis V; Zinonos I; Labrinidis A; Hay S; Ponomarev V; Panagopoulos V; Zysk A; DeNichilo M; Ingman W; Atkins GJ; Findlay DM; Zannettino AC; Evdokiou A
    Cancer Med; 2016 Mar; 5(3):534-45. PubMed ID: 26749324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A phase 1 'window-of-opportunity' trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients.
    Larue RT; Van De Voorde L; Berbée M; van Elmpt WJ; Dubois LJ; Panth KM; Peeters SG; Claessens A; Schreurs WM; Nap M; Warmerdam FA; Erdkamp FL; Sosef MN; Lambin P
    BMC Cancer; 2016 Aug; 16():644. PubMed ID: 27535748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of hypoxia-activated prodrug evofosfamide (TH-302) and ifosfamide in preclinical non-small cell lung cancer models.
    Sun JD; Liu Q; Ahluwalia D; Ferraro DJ; Wang Y; Jung D; Matteucci MD; Hart CP
    Cancer Biol Ther; 2016 Apr; 17(4):371-80. PubMed ID: 26818215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anticancer efficacy of the hypoxia-activated prodrug evofosfamide is enhanced in combination with proapoptotic receptor agonists against osteosarcoma.
    Liapis V; Zysk A; DeNichilo M; Zinonos I; Hay S; Panagopoulos V; Shoubridge A; Difelice C; Ponomarev V; Ingman W; Atkins GJ; Findlay DM; Zannettino ACW; Evdokiou A
    Cancer Med; 2017 Sep; 6(9):2164-2176. PubMed ID: 28799237
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of the hypoxia-activated prodrug evofosfamide (TH-302) in nasopharyngeal carcinoma in vitro and in vivo.
    Huang Y; Tian Y; Zhao Y; Xue C; Zhan J; Liu L; He X; Zhang L
    Cancer Commun (Lond); 2018 May; 38(1):15. PubMed ID: 29764490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase IB study of sorafenib and evofosfamide in patients with advanced hepatocellular and renal cell carcinomas (NCCTG N1135, Alliance).
    Tran NH; Foster NR; Mahipal A; Byrne T; Hubbard J; Silva A; Mody K; Alberts S; Borad MJ
    Invest New Drugs; 2021 Aug; 39(4):1072-1080. PubMed ID: 33646489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activity of the hypoxia-activated pro-drug TH-302 in hypoxic and perivascular regions of solid tumors and its potential to enhance therapeutic effects of chemotherapy.
    Saggar JK; Tannock IF
    Int J Cancer; 2014 Jun; 134(11):2726-34. PubMed ID: 24338277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular Imaging of Extracellular Tumor pH to Reveal Effects of Locoregional Therapy on Liver Cancer Microenvironment.
    Savic LJ; Schobert IT; Peters D; Walsh JJ; Laage-Gaupp FM; Hamm CA; Tritz N; Doemel LA; Lin M; Sinusas A; Schlachter T; Duncan JS; Hyder F; Coman D; Chapiro J
    Clin Cancer Res; 2020 Jan; 26(2):428-438. PubMed ID: 31582517
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of metabolic and immunologic responses to transarterial chemoembolization with different chemoembolic regimens in a rabbit VX2 liver tumor model.
    Doemel LA; Santana JG; Savic LJ; Gaupp FML; Borde T; Petukhova-Greenstein A; Kucukkaya AS; Schobert IT; Hamm CA; Gebauer B; Walsh JJ; Rexha I; Hyder F; Lin M; Madoff DC; Schlachter T; Chapiro J; Coman D
    Eur Radiol; 2022 Apr; 32(4):2437-2447. PubMed ID: 34718844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study.
    Brenner A; Zuniga R; Sun JD; Floyd J; Hart CP; Kroll S; Fichtel L; Cavazos D; Caflisch L; Gruslova A; Huang S; Liu Y; Lodi A; Tiziani S
    Neuro Oncol; 2018 Aug; 20(9):1231-1239. PubMed ID: 29415215
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia-Activated Prodrug Evofosfamide Treatment in Pancreatic Ductal Adenocarcinoma Xenografts Alters the Tumor Redox Status to Potentiate Radiotherapy.
    Kishimoto S; Brender JR; Chandramouli GVR; Saida Y; Yamamoto K; Mitchell JB; Krishna MC
    Antioxid Redox Signal; 2021 Oct; 35(11):904-915. PubMed ID: 32787454
    [No Abstract]   [Full Text] [Related]  

  • 16. Impact of Tumour Hypoxia on Evofosfamide Sensitivity in Head and Neck Squamous Cell Carcinoma Patient-Derived Xenograft Models.
    Harms JK; Lee TW; Wang T; Lai A; Kee D; Chaplin JM; McIvor NP; Hunter FW; Macann AMJ; Wilson WR; Jamieson SMF
    Cells; 2019 Jul; 8(7):. PubMed ID: 31337055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Transhepatic arterial embolization with superparamagnetic iron oxide and lipiodol for the treatment of VX2 tumor in rabbits].
    Liang Q; Deng L; Feng Z; Liu X; Ding J; Hu P; Wang W
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2017 Nov; 42(11):1248-1256. PubMed ID: 29187650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies.
    Hegde A; Jayaprakash P; Couillault CA; Piha-Paul S; Karp D; Rodon J; Pant S; Fu S; Dumbrava EE; Yap TA; Subbiah V; Bhosale P; Coarfa C; Higgins JP; Williams ET; Wilson TF; Lim J; Meric-Bernstam F; Sumner E; Zain H; Nguyen D; Nguyen LM; Rajapakshe K; Curran MA; Hong DS
    Clin Cancer Res; 2021 Jun; 27(11):3050-3060. PubMed ID: 33771853
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect of curcumin liposome after transcatheter arterial embolization in VX2 rabbits.
    Zhang X; Dai F; Chen J; Xie X; Xu H; Bai C; Qiao W; Shen W
    Cancer Biol Ther; 2019; 20(5):642-652. PubMed ID: 30621501
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma.
    Kloeckner R; Weinmann A; Prinz F; Pinto dos Santos D; Ruckes C; Dueber C; Pitton MB
    BMC Cancer; 2015 Jun; 15():465. PubMed ID: 26059447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.